Literature DB >> 10725093

Structural characterization, kinetic studies, and in vitro biological activity of new cis-diamminebis-cholylglycinate(O,O') Pt(II) and cis-diamminebis-ursodeoxycholate(O,O') Pt(II) complexes.

J J Criado1, M F Domínguez, M Medarde, E R Fernández, R I Macías, J J Marín.   

Abstract

The complexes cis-diamminebis-cholylglycinate (O,O') [Pt(II) C(52)H(90)N(4)O(12)Pt, for convenience referred to as Bamet-R1] and cis-diamminebis-ursodeoxycholate (O,O') Pt(II) (C(48)H(84)N(2)O(8)Pt, Bamet-UD2) were prepared. The structural integrity of the compounds was confirmed by elemental analysis, FT-IR, NMR, FAB-MS, and UV spectroscopies. The kinetic study of both compounds was accomplished by combining the conductivity measurement and those of the analysis of the electronic spectra in aqueous solution for NaCl concentrations of 4 mM (similar to cytoplasmatic concentration), 150 mM (similar to plasmatic concentration), and 500 mM. In water, the compound Bamet-R1 showed a half-life, t(1/2), of 3.0 h. This compound forms the chelate species through loss of a ligand, and the other one acts as a bidentate ligand. Ring opening in the presence of chloride ion was produced with a k(Cl)()-of 0.25 M(-)(1) h(-)(1). The half-life of Bamet-UD2 in aqueous solution was 3.2 h. However, since this species is not able to chelate and has a lower degree of solubility in the presence of chloride ion, its kinetic behavior was very different from that of the other compound. We consider this to be of great interest with regards to its cytostatic activity. All kinetic measurements were performed under pseudo-first-order conditions, and a pseudo-first-order behavior was found. The antitumoral effect of Bamet-UD2 on several cell lines derived from rat hepatoma, human hepatoma, mouse leukemia, and human colon carcinoma was found to be, in general, similar to that of cisplatin, but higher than that observed for Bamet-R1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725093     DOI: 10.1021/bc9901088

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

Review 1.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 2.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

Review 3.  Exploitation of bile acid transport systems in prodrug design.

Authors:  Elina Sievänen
Journal:  Molecules       Date:  2007-08-16       Impact factor: 4.411

4.  New fluorescent antitumour cisplatin analogue complexes. Study of the characteristics of their binding to DNA by flow injection analysis.

Authors:  A Alonso; M J Almendral; Y Curto; J J Criado; E Rodríguez; J L Manzano
Journal:  J Fluoresc       Date:  2007-06-08       Impact factor: 2.525

5.  Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1.

Authors:  Elisa Herraez; Laura Sanchez-Vicente; Rocio I R Macias; Oscar Briz; Jose J G Marin
Journal:  Oncotarget       Date:  2017-05-23

Review 6.  Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma.

Authors:  Jose J G Marin; Rocio I R Macias; Candela Cives-Losada; Ana Peleteiro-Vigil; Elisa Herraez; Elisa Lozano
Journal:  Cells       Date:  2020-02-21       Impact factor: 6.600

7.  Synthesis of New Cisplatin Derivatives from Bile Acids.

Authors:  Barbara Seroka; Zenon Łotowski; Agnieszka Hryniewicka; Lucie Rárová; Rafal R Sicinski; Aneta M Tomkiel; Jacek W Morzycki
Journal:  Molecules       Date:  2020-02-04       Impact factor: 4.411

Review 8.  Plasma membrane transporters in modern liver pharmacology.

Authors:  Jose J G Marin
Journal:  Scientifica (Cairo)       Date:  2012-10-14

Review 9.  Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.

Authors:  Rocio I R Macias
Journal:  ISRN Hepatol       Date:  2014-02-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.